{
    "nctId": "NCT03624881",
    "officialTitle": "Evaluation of the VISITAG SURPOINT\u2122 Module With External Processing Unit (EPU) When Used With the THERMOCOOL SMARTTOUCH\u00ae SF and the THERMOCOOL SMARTTOUCH\u00ae Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA)",
    "inclusionCriteria": "Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n1. Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment. Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry strip\n2. Failed at least one antiarrhythmic drug (AAD) (Class I or III antiarrhythmic drugs) as evidenced by recurrent symptomatic AF, or intolerable to the AAD\n3. Age 18 years or older\n4. Signed Patient Informed Consent Form (ICF)\n5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "Subjects who meet any of the following exclusion criteria are not eligible for enrollment.\n\n1. Previous surgical or catheter ablation for atrial fibrillation\n2. Previous cardiac surgery (including CABG) within the past 6 months (180 days)\n3. Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)\n4. Any carotid stenting or endarterectomy\n5. Documented LA thrombus on imaging\n6. LA size \\> 50 mm (parasternal long axis view)\n7. LVEF \\< 40%\n8. Contraindication to anticoagulation (heparin or warfarin)\n9. History of blood clotting or bleeding abnormalities\n10. PCI/MI within the past 2 months (60 days)\n11. Documented thromboembolic event (including TIA) within the past 12 months (365 days)\n12. Rheumatic Heart Disease\n13. Uncontrolled heart failure or NYHA function class III or IV\n14. Severe mitral regurgitation (Regurgitant volume \u2265 60 mL/beat, Regurgitant fraction \u2265 50%, and/or Effective regurgitant orifice area \u2265 0.40cm2)\n15. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days)\n16. Unstable angina\n17. Acute illness or active systemic infection or sepsis\n18. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.\n19. Presence of implanted ICD/CRT-D.\n20. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.\n21. Gastroesophageal Reflux Disease (GERD; active requiring significant intervention not including OTC medication)\n22. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.\n23. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)\n24. Concurrent enrollment in an investigational study evaluating another device, biologic, or drug.\n25. Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes vascular access, or manipulation of the catheter.\n26. Life expectancy less than 12 months"
}